Radiosurgery in the management of brain metastasis: a retrospective single-center study comparing Gamma Knife and LINAC treatment
- PMID: 28338441
- DOI: 10.3171/2016.10.JNS161480
Radiosurgery in the management of brain metastasis: a retrospective single-center study comparing Gamma Knife and LINAC treatment
Abstract
OBJECTIVE The authors present a retrospective analysis of a single-center experience with treatment of brain metastases using Gamma Knife (GK) and linear accelerator (LINAC)-based radiosurgery and compare the results. METHODS From July 2010 to July 2012, 63 patients with brain metastases were treated with radiosurgery. Among them, 28 (with 83 lesions) were treated with a GK unit and 35 (with 47 lesions) with a LINAC. The primary outcome was local progression-free survival (LPFS), evaluated on a per-lesion basis. The secondary outcome was overall survival (OS), evaluated per patient. Statistical analysis included standard tests and Cox regression with shared-frailty models to account for the within-patient correlation. RESULTS The mean follow-up period was 11.7 months (median 7.9 months, range 1.7-32 months) for GK and 18.1 months (median 17 months, range 7.5-28.7 months) for LINAC. The median number of lesions per patient was 2.5 (range 1-9) in the GK group and 1 (range 1-3) in the LINAC group (p < 0.01, 2-sample t-test). There were more radioresistant lesions (e.g., melanoma) and more lesions located in functional areas in the GK group. Additional technical reasons for choosing GK instead of LINAC were limitations of LINAC movements, especially if lesions were located in the lower posterior fossa or multiple lesions were close to highly functional areas (e.g., the brainstem), precluding optimal dosimetry with LINAC. The median marginal dose was 24 Gy with GK and 20 Gy with LINAC (p < 0.01, 2-sample t-test). For GK, the actuarial LPFS rate at 3, 6, 9, 12, and 17 months was 96.96%, 96.96%, 96.96%, 88.1%, and 81.5%, remaining stable until 32 months. For LINAC the rate at 3, 6, 12, 17, 24, and 33 months was 91.5%, 91.5%, 91.5%, 79.9%, 55.5%, and 17.1% (log-rank p = 0.03). In the Cox regression with shared-frailty model, the risk of local progression in the LINAC group was almost twice that of the GK group (HR 1.92, p > 0.05). The mean OS was 16.0 months (95% CI 11.2-20.9 months) in the GK group, compared with 20.9 months (95% CI 16.4-25.3 months) in the LINAC group. Univariate and multivariate analysis showed that a lower graded prognostic assessment (GPA) score, noncontrolled systemic status at last radiological assessment, and older age were associated with lower OS; after adjustment of these covariables by Cox regression, the OS was similar in the 2 groups. CONCLUSIONS In this retrospective study comparing GK and LINAC-based radiosurgery for brain metastases, patients with more severe disease were treated by GK, including those harboring lesions of greater number, of radioresistant type, or in highly functional areas. The risk of local progression for the LINAC group was almost twice that in the GK group, although the difference was not statistically significant. Importantly, the OS rates were similar for the 2 groups, although GK was used in patients with more complex brain metastatic disease and with no other therapeutic alternative.
Keywords: GK = Gamma Knife; GPA = graded prognostic assessment; GTV = gross tumor volume; Gamma Knife surgery; HR = hazard ratio; IQR = interquartile range; KPS = Karnofsky Performance Status; LINAC = linear accelerator; LPFS = local progression–free survival; OS = overall survival; PTV = planning target volume; RPA = recursive partitioning analysis; SIR = score index for radiosurgery; WBRT = whole-brain radiotherapy; brain metastases; linear accelerator; oncology; stereotactic radiosurgery.
Similar articles
-
Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.J Neurosurg. 2015 Nov;123(5):1261-7. doi: 10.3171/2014.12.JNS141919. Epub 2015 Jul 3. J Neurosurg. 2015. PMID: 26140482
-
Changing practice patterns of Gamma Knife versus linear accelerator-based stereotactic radiosurgery for brain metastases in the US.J Neurosurg. 2016 Apr;124(4):1018-24. doi: 10.3171/2015.4.JNS1573. Epub 2015 Oct 16. J Neurosurg. 2016. PMID: 26473783
-
Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.J Neurosurg. 2014 Dec;121 Suppl:75-83. doi: 10.3171/2014.6.GKS14708. J Neurosurg. 2014. PMID: 25434940
-
Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach.Expert Rev Anticancer Ther. 2016 Jul;16(7):731-40. doi: 10.1080/14737140.2016.1190648. Epub 2016 Jun 3. Expert Rev Anticancer Ther. 2016. PMID: 27186849 Review.
-
Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis.Neurosurg Focus. 2019 Jun 1;46(6):E2. doi: 10.3171/2019.3.FOCUS1970. Neurosurg Focus. 2019. PMID: 31153149
Cited by
-
Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform.Radiat Oncol. 2023 Feb 7;18(1):28. doi: 10.1186/s13014-023-02216-5. Radiat Oncol. 2023. PMID: 36750848 Free PMC article. Clinical Trial.
-
Let's make size not matter: tumor control and toxicity outcomes of hypofractionated Gamma Knife radiosurgery for large brain metastases.J Neurooncol. 2023 Jul;163(3):587-595. doi: 10.1007/s11060-023-04365-9. Epub 2023 Jul 6. J Neurooncol. 2023. PMID: 37410346
-
Health-related quality of life after stereotactic radiosurgery in patients with brain metastases.Support Care Cancer. 2023 Nov 27;31(12):720. doi: 10.1007/s00520-023-08203-6. Support Care Cancer. 2023. PMID: 38008876
-
Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).Radiat Oncol. 2018 Jul 28;13(1):138. doi: 10.1186/s13014-018-1083-1. Radiat Oncol. 2018. PMID: 30055640 Free PMC article.
-
Genomic analysis of human brain metastases treated with stereotactic radiosurgery reveals unique signature based on treatment failure.iScience. 2024 Mar 27;27(4):109601. doi: 10.1016/j.isci.2024.109601. eCollection 2024 Apr 19. iScience. 2024. PMID: 38623341 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
